New data from diabetes prevention programme shows a reduction of type 2 diabetes
pharmafile | June 17, 2020 | News story | Research and Development |Â Â diabetes, type 2 diabetesÂ
The Diabetes Prevention Program Outcomes Study (DPPOS) of 2,000 people showed a significant reduction in the participants’ risk of developing type 2 diabetes when they pursued weight loss programs or metformin treatment.
These latest results were outlined at the 80th virtual scientific sessions from the American Diabetes Association. The DPPOS is a long term follow up to the Diabetes Prevention Program (DPP) which ran from 1996 to 2001. The results of the original study showed that type 2 diabetes development was decreased by 58% from a lifestyle intervention and 31% from metformin treatment, compared to a placebo.
75% of the participants in the original study also were part of the follow up DPPOS, which includes both those who have developed diabetes and those who have not. Since the average age of the participants is now 72, an assessment of how health factors that are caused by ageing contribute to the development and progression of type 2 diabetes was carried out.
The newest results showed that the intensive lifestyle intervention group had a long-term reduction in the development of frailty. Those participants who did not develop diabetes had a significantly lower risk of developing early stages of eye and kidney disease, while the prevention effects in the original lifestyle group and metformin treatment group remain 22 years after the start of the study, with a 25% and 18% reduced risk of diabetes development.
Dr David M. Nathan, DPPOS chair and Director of the Clinical Research Center and Diabetes Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School, said: “The DPP/DPPOS is the longest duration and largest prevention study that continues to actively follow its participants.”
“The current results indicate that prevention of type 2 diabetes is possible and has important clinical benefits. The long-term benefits of the two DPP interventions on diabetes development, still present many years after they were started, are a testament to the power of these interventions and reinforce their importance in the reduction of diabetes.”
The Centers for Disease Control and Prevention are now offering the National Diabetes Prevention Program across the US.
Conor Kavanagh
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
